– SWITZERLAND, Saint-Prex – Ferring Pharmaceuticals today announced the appointment of Jean-Frédéric Paulsen as Group Executive Chairman effective from 1st July 2023, replacing Lars Rebien Sørensen who will remain on the Board as Vice-Chairman.
The company also announced the appointments of Viviane Monges and Henrik Normann to the Board of Directors effective from 1st July 2023
“I am pleased to support the new Executive Chairman during a period of transition as he takes on greater responsibilities from the Chairman Emeritus. I would like to welcome the new members of the Board of Directors,” said Lars Rebien Sørensen.
Viviane Monges joins the Audit and Finance Committee as Chair replacing Hélène Ploix, who has stood down from the Board of Directors.
Concurrently, Jeff Hobbs and Alexandra, Countess of Frederiksborg, have stood down from the Board of Directors.
About Viviane Monges
Ms. Monges previously held senior corporate positions in the life sciences and consumer sectors. She was CFO at Wyeth Pharmaceuticals/Pfizer, Novartis, and Galderma before becoming VP of Business Excellence Finance & Control at Nestlé.
About Henrik Normann
Henrik Normann has previously been President and CEO of Nordic Investment Bank, the international financial institution of the Nordic and Baltic countries. He spent much of his career at Danske Bank, starting as a management trainee in 1983 and later becoming Head of Danske Bank in Denmark and Global Head of Danske Markets.
About Jean-Frédéric Paulsen
Mr. Paulsen, who joined the Board of Directors1 in July 2021, played a leading role in securing the US approval of Adstiladrin.
Jean-Frédéric Paulsen said: “I am honoured to take over responsibility for the Ferring Group, which was founded by my grandfather Dr. Frederik Paulsen and his wife, Eva Paulsen, in 1950 and chaired by my father for more than 30 years. Under their leadership, Ferring has established a global reputation as a leader in reproductive medicine, maternal health, and numerous specialty areas of medicine. I look forward to building on our heritage and strong foundations to lead Ferring into an exciting new era as we establish a pioneering presence in areas such as uro-oncology and the microbiome.”
Mr. Paulsen has been Chairman of Ferring Ventures SA and FinVector Oy since 2020 and previously served as Senior Advisor to four Ministers of Economy and Sustainable Development in Georgia. He began his career working at Mars Inc., Coca-Cola, and Credit Suisse.
Mr. Paulsen holds a Master’s degree in Finance from the London School of Economics and Political Science and is a Fellow of the Chartered Institute of Management Accountants in the UK.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health and specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has subsidiaries in over 50 countries and markets its products in over 100 countries.
Source: https://www.ferring.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.